Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

# Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor

## Abstract

Beta-lactamase inhibitors are increasingly used to counteract antibiotic resistance mediated by beta-lactamase enzymes. These inhibitors compete with the beta-lactam antibiotic for the same binding site on the beta-lactamase, thus generating an evolutionary tradeoff: mutations that increase the enzyme’s beta-lactamase activity tend to increase also its susceptibility to the inhibitor. Here, we investigate how common and accessible are mutants that escape this adaptive tradeoff. Screening a deep mutant library of the blaampC beta-lactamase gene of Escherichia coli, we identified mutations that allow growth at beta-lactam concentrations far exceeding those inhibiting growth of the wildtype strain, even in the presence of the enzyme inhibitor (avibactam). These escape mutations are rare and drug-specific, and some combinations of avibactam with beta-lactam drugs appear to prevent such escape phenotypes. Our results, showing differential adaptive potential of blaampC to combinations of avibactam and different beta-lactam antibiotics, suggest that it may be possible to identify treatments that are more resilient to evolution of resistance.

## Introduction

Resistance to beta-lactam antibiotics, mediated primarily through beta-lactamases, is growing as a major threat to public health. Beta-lactams are commonly used for the treatment of a range of bacterial pathogens, constituting the most widely prescribed antibiotic class1,2. These antibiotics are characterized by a core of a beta-lactam ring and are classified by their moieties into four major families: penicillins, cephalosporins, carbapenems, and monobactams3. The irreversible binding of these drugs to the peptidoglycan cross-linking enzymes (Penicillin Binding Proteins, PBPs) leads to cell death and lysis. Resistance to beta-lactams has become widespread in recent years, mainly through drug degradation by beta-lactamases, most notably by the serine beta-lactamases of classes A and C4,5. Hydrolyzing the core beta-lactam ring, these enzymes decrease the effective drug concentration, thereby conferring increased resistance6,7,8. The effectiveness of these enzymes is often further improved either by mutations that increase their expression or by intragenic structural mutations that enhance their efficacy and specificity9,10,11,12,13,14. To overcome beta-lactamase mediated antibiotic resistance, beta-lactam antibiotic treatments are often supplemented by a beta-lactamase inhibitor15,16,17. These inhibitors compete with the drug for the same binding site, yet being resilient to degradation they block enzyme activity thereby restoring antibiotic efficacy. While class A beta-lactamase inhibitors, such as clavulanate or tazobactam, are commonly used, efficient inhibitors of the widespread class C beta-lactamases have only recently been introduced.

Class C beta-lactamases confer resistance to broad-spectrum cephalosporins, penicillins, and monobactams18,19. Like other beta-lactamases, they are highly transferable and widespread among Gram-negative bacteria, especially in clinical isolates20,21. Class C beta-lactamases catalyze the hydrolysis of the beta-lactam ring by a conserved catalytic Serine (Ser 64 in Escherichia coli blaampC) and an activating conserved Tyrosine (Tyr 150)19,22,23,24. A major obstacle to effective treatment of pathogens that carry class C beta-lactamases is the insensitivity of the enzyme to classical beta-lactamase inhibitors; the different structure of the pocket of class C enzymes compared to class A prevents the classical inhibitors from binding to its pocket25,26. Avibactam is a novel non-beta-lactam molecule that inhibits the activity of class C as well as of other beta-lactamases27,28,29. It is resilient to class C beta-lactamase hydrolysis and inhibits their activity by binding the catalytic Serine covalently yet reversibly28. Avibactam can substantially decrease the resistance level of class C beta-lactamase-carrying bacteria to beta-lactam drugs30. Indeed, avibactam was recently approved for clinical use in combination with the cephalosporin ceftazidime and a combination of avibactam with the monobactam aztreonam is currently in clinical trials31,32. It is therefore important to understand the potential for evolutionary adaptation of the enzyme to combinations of avibactam with different beta-lactams.

Resistance to beta-lactamase inhibitors is typically associated with increased susceptibility to beta-lactam drugs, representing inherent constraints on adaptive mutations. While mutations that increase beta-lactamase expression can increase resistance to the drug alone and in combination with the inhibitor, resistance to the drug-inhibitor treatment via structural intragenic mutations is inherently constrained: due to the structural similarity between the drug and the inhibitor, mutations that increase drug degradation also tend to increase the affinity of the enzyme to the inhibitor7,33,34,35,36,37,38. Of course, this functional tradeoff between resistance to the drug and the inhibitor does not completely preclude mutations that increase resistance to the combination39,40,41,42. Indeed, even without escaping this tradeoff, a mutation providing strong resistance to one compound, even at the cost of mild sensitivity to the other, can provide an overall increased resistance to the combination34,41,42. Less is known though about mutations that escape this tradeoff, allowing the mutant to survive, even in the presence of the inhibitor, at drug concentrations that kill the wild-type in the absence of the inhibitor (native inhibitory concentration). In particular, it is unclear how prevalent are such escape mutations, how specific they are to different beta-lactams and whether they might be accessible via a single amino-acid substitution.

Here, focusing on E. coli BlaampC enzyme as a model for class C beta-lactamases, we constructed a systematic single amino-acid substitution mutant library and identified resistance and escape mutations to avibactam paired with different beta-lactam drugs. Measuring growth of the mutants across gradients of different drugs, with and without avibactam, we found that escape mutations are accessible but only for some drugs and not others. These escape mutations allow bacteria to grow even at the presence of avibactam at the high drug concentrations required to kill the wild-type without avibactam. Sequencing the selected mutant library, we identified these escape mutations and found that they are rare and drug-specific.

## Results

### Deep mutant library of blaampC

To systematically study the tradeoffs between mutations that confer resistance to beta-lactam and beta-lactamase inhibitors, we constructed a library of mutants inside the beta-lactamase encoding gene, blaampC. First, we identified in silico 44 residues at and in the near vicinity of the active pocket of the BlaampC enzyme (Methods; Supplementary Fig. 1). Next, starting with an E. coli parental strain expressing the chromosomal blaampC, we systematically mutated these intragenic positions using Multiplexed Automated Genome Engineering (MAGE, Fig. 1a; Methods)43,44,45. Our design guaranteed that each mutated codon differed from the wild-type codon by 2–3 nucleotides, thereby much reducing misidentifications caused by sequencing errors (Methods, Supplementary Data 1; this 2-mutation constraint still allows access to the vast majority of possible amino-acid changes: 846 out of the potential 44 ×(19 amino acids + stop) = 880 single substitution mutants, 96%). The mutant library contained 93.4% of these designed single amino-acid substitutions, with mutant frequencies distributed with an average and standard deviation of 5.3 × 10−5 ± 4.2 × 10−5 (as identified by amplicon sequencing using Illumina’s MiSeq, Methods, Supplementary Fig. 2).

### Escape phenotype is observed by growth measurements

To characterize the level of resistance that mutations in blaampC can confer, we pooled all the MAGE mutants and selected the pooled library on gradients of five different antibiotics, representing all major beta-lactam families: the penicillins piperacillin (PIP) and ampicillin (AMP); the monobactam aztreonam (ATM); the cephalosporin cefepime (FEP); and the carbapenem meropenem (MER). Each drug was applied with or without the beta-lactamase inhibitor avibactam (AVI). Culture density was monitored over time for the mutant library as well as the parental strain (WT, expressing unmutated blaampC). As drug concentration increased, the cultures took longer to reach detectable OD, yet grew at similar rates (Fig. 2a). To characterize these time delays we measured tth, the time in which culture density crossed a set threshold, ODth. Next, for each drug concentration, we represented the measured delay by an estimated initial density of resistant mutants $$OD_{{\mathrm{Res}}}^0 = {\mathrm{OD}}_{{\mathrm{th}}} \cdot e^{ - g \cdot t_{{\mathrm{th}}}}$$, where g is bacterial growth rate (Fig. 2a; Supplementary Fig. 3). Plotting $${\mathrm{OD}}_{{\mathrm{Res}}}^0$$ against drug concentration, we defined the critical drug concentration η at which the expected initial density of the mutants drops below an OD value corresponding to the expected number of cells of a typical MAGE mutant ($$OD_{{\mathrm{Res}}}^0(\eta ) = {\mathrm{OD}}_{{\mathrm{single}}\;{\mathrm{mutant}}}$$, where $${\mathrm{OD}}_{{\mathrm{single}}\,{\mathrm{mutant}}}$$=3.3 × 10−8, Methods). For each of the tested antibiotics (AB), we interpolated this critical drug concentration needed to prevent the growth of all initially present mutants for both the wild-type ($$\eta _{{\mathrm{AB}}}^{{\mathrm{WT}}}$$) and the MAGE library ($$\eta _{{\mathrm{AB}}}^{{\mathrm{MAGE}}}$$, Fig. 2b). We also subjected these same cultures to gradients of the same drugs in the presence of 0.25 μg/ml avibactam and determined the corresponding critical drug concentrations ($$\eta _{{\mathrm{AB}}}^{{\mathrm{WT}}}|^{{\mathrm{AVI}}}$$, $$\eta _{{\mathrm{AB}}}^{{\mathrm{MAGE}}}|^{{\mathrm{AVI}}}$$, Fig. 2b).

Wild-type BlaampC mediated resistance varied substantially for different drugs, as well as its potential for resistance improving mutations. Supplementing cultures with avibactam lowered the resistance of the wild-type to piperacillin, aztreonam, cefepime and ampicillin (Fig. 2b), but not to meropenem (Supplementary Fig. 4) indicating that active BlaampC confers differential resistance to these drugs. Considering the phenotypes of the wild-type blaampC and the MAGE mutant library without avibactam, we found that while no intragenic mutations in blaampC led to increased ampicillin resistance, resistance to the other three drugs vastly improved (Fig. 2b, triangles). We next asked whether these mutations that increase resistance to piperacillin, aztreonam and cefepime in the absence of avibactam can possibly also escape the drug-inhibitor tradeoff.

Contrasting the drug concentration required to inhibit the mutant library in the presence of avibactam with the native inhibitory concentration, we find that escape mutations are accessible for some drugs and are not accessible in others. While no escape mutants are observed for piperacillin ($$\eta _{{\mathrm{PIP}}}^{{\mathrm{MAGE}}}|^{{\mathrm{AVI}}} < \eta _{{\mathrm{PIP}}}^{{\mathrm{WT}}}$$, left-pointing arrow, Fig. 2b), escape mutations do appear for aztreonam and cefepime ($$\eta _{{\mathrm{ATM}}}^{{\mathrm{MAGE}}}|^{{\mathrm{AVI}}} > \eta _{{\mathrm{ATM}}}^{{\mathrm{WT}}}$$ and $$\eta _{{\mathrm{FEP}}}^{{\mathrm{MAGE}}}|^{{\mathrm{AVI}}} > \eta _{{\mathrm{FEP}}}^{{\mathrm{WT}}}$$, right-pointing arrow). To identify the genetic determinants of such escape mutations, we next analyzed the specific mutations leading to resistance to beta-lactam drugs and to drug-inhibitor combinations.

### Drug-resistant mutants identified by amplicon sequencing

To identify resistance-conferring mutations, we applied amplicon deep sequencing to a mutant library selected on gradients of beta-lactam drugs. First, to allow Illumina sequencing of the entire MAGE library, we pooled the 44-residue MAGE mutant libraries into two pools based on their position in the primary sequence. Second, we enriched these two pools for resistant mutants by selection on gradients of beta-lactam drugs with and without avibactam, then pooling cultures that grew on high drug concentrations to establish “enriched mutant libraries”. Finally, we subjected duplicates of these two enriched mutant libraries on gradients of different beta-lactams with and without avibactam, recorded OD and chose a comprehensive subset of cultures for amplicon sequencing (Supplementary Fig. 5; Illumina MiSeq, Methods). Analyzing the amplicon reads, we identified, for each condition, the abundance of the WT and each of the mutants (Methods). Then, to estimate the resistance level of each mutant to each of the drugs ($$IC50_{{\mathrm{AB}}}^{{\mathrm{Mut}}}$$), we fitted the measured abundance data of each of the mutants across all drug concentrations with a dose-response model and determined the drug concentration that inhibits the mutant growth by 50% (Fig. 3a, Methods; Supplementary Fig. 6; Supplementary Data 2).

Analyzing the inhibitory concentrations of each of the mutants, we found that resistance to different drugs is mediated through only partially overlapping sets of mutations. Determining the IC50 of all mutants ($${\mathrm{IC}}50_{{\mathrm{AB}}}^{{\mathrm{Mut}}}$$), we identified, for each of the drugs, residues for which multiple beneficial substitutions exist (Fig. 3a, R148 for FEP; Y150 for ATM; E272 and N289 for PIP; S287 for both PIP and FEP). The diversity of beneficial substitutions for each of these residues indicates that these positions were maladapted (Fig. 3a). These residues were usually essential for BlaampC activity on other drugs, possibly explaining their maladaptiveness (Fig. 3b). We further identified many mutations conferring high levels of resistance to both piperacillin and cefepime, but no cross high-resistance between aztreonam and the other drugs was found (Fig. 3b). However, a single mutation, E272I, had a small effect that extended over the three drugs (Fig. 3b). To link the mutations that affect drug resistance to the enzyme structure and its active site, we computationally docked each of our compounds to a free BlampC enzyme (AutoDock Vina46; Fig. 3c; Methods). We found that while substitutions of residues in loop H10 (Fig. 3c green, residues 287–296) to Glycine or Proline tend to confer resistance to both piperacillin and cefepime, they tend to have a negative effect on resistance to aztreonam (Fig. 3a). Such mutations are expected to destabilize the helix structure into a loop47 and hence can make more space for piperacillin and cefepime that carry a large ring adjacent to the beta-lactam ring. Similarly, we found multiple substitutions of the conserved Y150 residue sensitizing towards cefepime and piperacillin, yet conferring resistance to aztreonam. These resistance-conferring mutations were next examined for their ability to escape the drug-inhibitor tradeoff.

### Escape mutations are rare and drug-specific

Pairing our measurements of mutant inhibitory concentrations for drug-only and drug-inhibitor combinations, we characterized the drug-inhibitor resistance tradeoffs and identified escape mutations. For each mutant, we compared the changes in resistance to the drugs with and without avibactam relative to the wild-type (Fig. 4; Supplementary Data 2).

As expected, mutants with increased resistance to the beta-lactam drugs were often more sensitive to avibactam and mutants with increased resistance to avibactam became more sensitive to the beta-lactam drugs (Fig. 5a-d). Mutants with increased resistance to both the drug and the drug-avibactam combination also appeared, but commonly these mutants too were not able to grow at the native inhibitory concentration required to inhibit the wild-type in absence of avibactam (Fig. 5b-d; orange shade with blue horizontal lines in Fig. 5a). Yet, importantly, some rare mutations did confer resistance to the drug beyond the native inhibitory concentration of the wild-type even in the presence of the inhibitor (1.2% of the mutants presented $${\mathrm{IC}}50_{{\mathrm{AB}}}^{{\mathrm{Mut}}}|^{{\mathrm{AVI}}} > {\mathrm{IC}}50_{{\mathrm{AB}}}^{{\mathrm{WT}}}$$; red vertically-dashed area Fig. 5a; Fig. 5c, d). In agreement with our phenotypic measurements (Fig. 2b), these escape mutants were only identified for aztreonam and cefepime and not for piperacillin. Moreover, even for cefepime and aztreonam, such mutations are rare and drug-specific. While substitutions of the conserved Y150 to non-aromatic positively charged amino acids (R, K), or small amino acids (G and A), as well as to S and P can escape the tradeoff between resistance to aztreonam and avibactam, they are sensitizing to cefepime and do not confer resistance to the cefepime-avibactam combination (Fig. 5c, d; each such substitution appears in all accessible codons in all drug concentrations). Conversely, mutations that alter N346 to the large volume amino acids F, Y, W as well as the S237H and R148P substitutions can escape the tradeoff between resistance to avibactam and cefepime but are sensitizing to aztreonam and hence do not escape the avibactam-aztreonam combination (Fig. 5c, d). While all amino-acid substitutions in our library are derived from more than one nucleotide change and hence less accessible evolutionary, three of the escape mutations identified are also accessible by a single nucleotide change (Y150S for aztreonam as well as N346Y and R148P for cefepime).

To validate and better characterize the escape phenotype, we constructed strains expressing two two of these mutant alleles, Y150A and N346W, under an inducible promoter, and challenged them on a 2-D gradient of avibactam and either aztreonam or cefepime respectively (Methods). Identifying the IC50 isobole, the line in concentration space where bacterial growth is inhibited by 50% (Fig. 5e, f; Supplementary Fig. 7; Methods), we found that these escape mutations indeed increase the resistance to the inhibitor-drug combination even above the high levels needed to kill the wild-type without avibactam.

To further estimate the prevalence of escape mutations, we tested five additional beta-lactam antibiotics: the penicillins oxacillin (OXA) and penicillin G (PEN) as well as the cephalosporins cefoxitin (FOX), cefazolin (CFZ), and ceftazidime (CAZ). We inoculated the MAGE mutant pools on gradients of each of the five drugs with and without AVI, measured bacterial density over time and calculated $$\eta$$, the critical concentration that inhibit the growth of pre-existing mutants (Methods; Supplementary Fig. 8). While weak escape phenotype appeared for ceftazidime, all other tested beta-lactams prevented substantial resistance to the drug-inhibitor combinations (Fig. 5g). The mutants that escaped the ceftazidime-avibactam tradeoff (R148N and N346P; Methods) were similar to mutations that escaped the tradeoff between avibactam and cefepime, which is also a cephalosporin (R148P and N346F/Y/W), suggesting fine-tuning of resistance to the specific beta-lactam class. Overall, of the ten tested antibiotics escape mutants were found only for aztreonam, cefepime, and ceftazidime highlighting the rarity of such mutations.

## Discussion

Systematically screening blaampC beta-lactamase mutants, we identified mutations that escape the tradeoff between resistance to beta-lactam drugs and to a beta-lactamase inhibitor. Our measurements show that such escape mutations appear only for some drug-inhibitor combinations, most prominently for FEP-AVI and ATM-AVI, and are rare and drug-specific. In these evolutionary susceptible drug-inhibitor combinations, even a single amino-acid change in the beta-lactamase enzyme BlaampC can confer resistance levels exceeding the native concentration that the wild-type can sustain without the inhibitor. In contrast, we identified no single amino-acid mutants which escapes the piperacillin-avibactam tradeoff.

The presence of escape mutations in specific drug combinations and their absence in others have implications for both mechanistic understanding and for refining diagnostics and treatment. The escape mutations identified were associated with the lack of a ring adjacent to the beta-lactam ring for aztreonam and with the stabilization of the ring in the R1 side-chain for cefepime. The lack of these two features in piperacillin may provide hints for the constraints of mutations that escape the piperacillin-avibactam tradeoff, yet specifically determining the structural mechanism remains a subject of future research. Independently of the mechanism, the specifically tested escape mutants enjoyed an ability to grow in the native inhibitory concentration of the beta-lactam drug at a wide range of avibactam concentrations. These robust phenotypes suggest that escape mutations can potentially jeopardize the treatment efficacy of bacterial pathogens by drug-inhibitor combinations. Future studies are needed to determine for each beta-lactam drug which of the different beta-lactamase inhibitors form a treatment combination that is most resilient to evolutionary escape. Treatment optimization can also be based on genome-based diagnostics which use the escape mutations as predictive markers. While further investigations of escape mutations in vitro and in vivo are required, our identification of drug-inhibitor combinations permissive and non-permissive to escape mutations can serve as basis for an evolutionary-informed choice of combination drug treatments which minimize the potential for resistance.

## Methods

### Identifying the BlaampC catalytic pocket

Residues delineating the catalytic pocket of BlaampC were selected by their distance from the ceftazidime drug bound to BlaampC enzyme in the 3D crystal structure (PDB ID: 1IEL). We defined two layers according to their distance to the drug, residues within 5Å from the bound drug form the first layer as many of them serve as hotspot for substrate binding or catalytic activity, while more distant residues within a distance from 5Å to 7Å from the drug form the second layer, which are generally linked to the maintenance of the pocket 3D structure.

### Preparing a MAGE-compatible blaampC-expressing E. coli

E. coli MG1655 bacteria were transformed with the pORTMAGE system45, an inducible MAGE system transferable on a plasmid. Next, five bases in the proximal promoter (−32, −18, −1, +5, +58) of blaampC were mutated by a MAGE protocol to activate blaampC expression48.

### Constructing the mutant library

We aimed at altering each codon of interest into all amino acids accessible by a two or three nucleotide change from the original codon. To do so in a cost-effective way we used two oligos for each codon. Those 90 bases ssDNA oligos have flanking sequences identical to the genomic sequence, with three ambiguous bases to alter the codon of choice (Supplementary Data 1; oligos MS_AmpC_{position}_{i}_p{j} where {position} describes the mutated residue in the gene including the 16 amino-acid signaling peptide, {i} is 1 or 2, and {j} is the number of the MAGE pool. Positions within 45 bases of each other were transformed together as a pool since due to the proximity every mutant will carry only a single amino-acid change). In both oligos, the last of these ambiguous bases, aimed at the wobble position of the codon, is a mix of the three non-native nucleotides (if the native nucleotide is A, the oligo contains either C, G or T in a 1:1:1 ratio). One oligo presents a mix of the three non-native codons in the first position and a mix of all four nucleotides in the second position, while the other oligo presents the four nucleotides in the first position and three non-native ones in the second. For example, an AGC codon code for Serine is altered by oligos with BND and NHD mixes where N stands for any of the four nucleotides, B for C/G/T, D for A/G/T, and H for A/C/T. That way we get 45 codons out of the 54 possible codons that satisfy at least two nucleotide differences from the original codon, yet we lose only 4% of the possible amino-acid substitutions (Supplementary Fig. 2). Each position of interest was targeted by two such oligos, and positions close enough to prevent double mutants were transformed together (Supplementary Data 1, pools p1-p10) by a standard MAGE protocol. In short, bacteria were grown in 2 ml LB at 30 °C to an optical density of 0.3 followed by activation of the MAGE system at 42 °C for 10 min. Next, the culture was put on ice for five minutes, washed twice in 50 ml double distilled water and transformed with ssDNA oligos by electrophoresis (1800V, 25μF, 200Ω) followed by recovery in rich medium (24 g/l Yeast extract, 12 g/l Tryptone, 9.4 g/l K2HPO4, 2 g/l KH2PO4). To enrich the mutant frequency, seven cycles of MAGE were applied before the libraries were pooled.

### Preparation of amplicon libraries and high-throughput sequencing

The DNA from cultures chosen for sequencing was extracted (NucleoSpin Tissue, Manchery-Nagel) and amplicon libraries were prepared by two consecutive PCR reactions targeting the regions of sequencing pool 1 (sp1, 141-624 in the blaampC gene) and sequencing pool 2 (sp2, 768-999 in the blaampC gene). A first, short reaction of 10 cycles was conducted with primers that target the genomic sequence and add flanking sequences identical to the 5’ region of Illumina adapters. Amplicon libraries have very low diversity, so to improve sequencing, diversity was added by designing primers with three phases from each direction (Supplementary Data 1, ampC_sp1_int F 1:3, ampC_sp1_int R 1:3, ampC_sp2_int R 1:3, ampC_sp2_int R 1:3). Next, the product was cleaned (AMPure XP beads, Beckman Coulter, by standard protocol) and was then used as a template for the second reaction of 25 cycles with primers that target the flanking ends of the product of the first PCR and contain Illumina adaptors and barcodes for sequencing (Supplementary Data 1, nx_i5, nx_i7). The products of the second reaction were cleaned and pooled equi-molarly (product concentration measured by Quant-iT, Thermo Fisher Scientific Q33130). Amplicon libraries were sequenced using Illumina MiSeq (250 paired-end using V2 chemistry) to yield a total of 7.5 × 106 reads. The sequencing reads covered the full amplicon of sequencing pool 2 and the majority of the amplicon of sequencing pool 1, except for a 50 bases gap in the middle. To cover this gap we additionally sequenced this library on Illumina MiSeq using custom intra-amplicon sequencing primers (Supplementary Data 1, ampC_seq_sp1 F, ampC_seq_sp1 R) using 150 bp nano protocol to yield smaller libraries with a total of 8.4 × 105 reads.

### Calculating mutant resistance levels from abundance data

To determine the IC50 of each mutant, we fitted the mutant abundance across the drug gradient to an expectation from a mathematical model accounting for the resistance level of each mutant and the competition among them. The model assumes a Hill-like dependence of the growth rate $$g_i(c)$$ of each mutant i on drug concentration c, $$g_i(c) = g^{{\mathrm{max}}}/( {1 + (c/{\mathrm{IC}}50_i)^h} )$$, where $$g^{{\mathrm{max}}}$$ is the growth rate in the absence of the drug, IC50i is the drug concentration that inhibits growth by 50%, and h is the Hill coefficient of the drug. The abundance of each mutant at the end of growth is simply $$N_i^{{\mathrm{final}}}(c) = N_i^{{\mathrm{initial}}}{\mathrm{exp}}\left( {g_i(c) \cdot t^{{\mathrm{final}}}} \right)$$ where $$N_i^{{\mathrm{initial}}}$$ is the initial abundance of the mutant as observed in the sequencing data of non-treated saturated cultures divided by the dilution factor been used to start the experiment (1:50), and tfinal is the duration of bacterial growth. We assume that the culture grows exponentially until the sampling time, $$t^{{\mathrm{sampling}}} = 16\,{\mathrm{h}}$$, unless already before this time the culture density reaches a saturation level $$N_{{\mathrm{Total}}}^{{\mathrm{Saturation}}}$$. The total growth time is, therefore, $$t^{{\mathrm{final}}} = {\mathrm{min}}(t^{{\mathrm{sampling}}},t^{{\mathrm{Saturation}}})$$, where $$t^{{\mathrm{Saturation}}}$$ is defined by $$N_{{\mathrm{Total}}}^{{\mathrm{Saturation}}} = \mathop {\sum}\limits_i {N_i^{{\mathrm{initial}}}{\mathrm{exp}}\left( {g_i(c) \cdot t^{{\mathrm{Saturation}}}} \right)}$$. The inhibitory concentrations for each drug IC50i were determined by fitting the model expected abundances $$N_i^{{\mathrm{final}}}(c)$$ to the corresponding deep sequencing-based duplicate measurements of each mutant at each drug concentration. Specifically, we used nonlinear fitting to minimize the error of predicted growth of all mutants in all cultures. These fitted IC50 is used as a measure of drug resistance.

### Docking the beta-lactam drugs to a BlaampC structure

To generate putative binding poses, we docked antibiotics using the AutoDock Vina software package version 1.1.2 (May 11, 2011) with the default scoring function. In the AutoDock Vina configuration files, the parameter num_modes was set to 20 and exhaustiveness to 48 to improve the searching space and accuracy. We identified the enzyme pocket based on the location of cephalothin on PDB ID 1KVL. We chose all the rotatable bonds in ligands to be flexible during the docking procedure, and we kept all the protein residues rigid. We assigned the Gasteiger atomic partial charges to the protein using the AutoDockTools package49. Antibiotics with their closed beta-lactam ring configuration were obtained from ZINC15 database50 and modified by Maestro (Schrodinger Inc. Release 2019, LLC, New York, NY.2018) if necessary. Ligands and enzyme were converted to PDBQT format. From the docking results, we chose those poses with the best energy and a similar 3D configuration of the beta-lactam ring when compared to cephalothin from 1KVL (first for FEP, second for PIP and 11th for ATM in the energy rank) and further analyzed with ChimeraX51.

### Measuring escape phenotype for Y150A and N346W mutants

To validate the escape phenotype of blaampC mutants Y150A and N346W, both mutants and a wild-type blaampC control were cloned and measured directly. The open reading frame of mutant and wild-type genes were synthesized and cloned into pUC57-Kan (GENEWIZ). The open reading frames were then amplified. During PCR EcoRI and BamHI restriction sites as well as a ribosomal binding site were added. The genes were cloned into the multiple cloning site of the pSTV28 plasmid under an IPTG inducible lac promoter.

### Calculating the IC50 isobole from growth data

Duplicate measurements of bacterial density after overnight growth in the presence of 30uM IPTG and under a range of drug concentrations, D, and avibactam concentrations, I, were taken, $${\mathrm{OD}}(D,I)$$. The IC50 isobole is the line in concentration space where bacterial growth is inhibited by 50%, $${\mathrm{OD}}(D,I) = {\mathrm{OD}}(0,0)/2$$.

### Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

The source data underlying all Figures are provided as a Source Data file. The nucleotide sequence datasets generated during and/or analysed during the current study are available in the European Nucleotide Archive (ENA) repository under accession code PRJEB36781. Further growth measurements are available on the lab website (https://kishony.technion.ac.il/resources/).

## Code availability

Matlab scripts used in the current study are publicly available on the lab website (https://kishony.technion.ac.il/resources/).

## References

1. 1.

Van Boeckel, T. P. et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect. Dis. 14, 742–750 (2014).

2. 2.

Yelin, I. et al. Personal clinical history predicts antibiotic resistance of urinary tract infections. Nat. Med. 25, 1143–1152 (2019).

3. 3.

Page, M. I. The mechanisms of reactions of.beta.-lactam antibiotics. Acc. Chem. Res. 17, 144–151 (1984).

4. 4.

Babic, M., Hujer, A. M. & Bonomo, R. A. What’s new in antibiotic resistance? Focus on beta-lactamases. Drug Resist. Updat. 9, 142–156 (2006).

5. 5.

Rossolini, G. M., Arena, F., Pecile, P. & Pollini, S. Update on the antibiotic resistance crisis. Curr. Opin. Pharmacol. 18, 56–60 (2014).

6. 6.

Ambler, R. P. The structure of β-lactamases. Philos. Trans. R. Soc. B: Biol. Sci. 289, 321–331 (1980).

7. 7.

Philippon, A., Labia, R. & Jacoby, G. Extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 33, 1131–1136 (1989).

8. 8.

Bush, K., Jacoby, G. A. & Medeiros, A. A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39, 1211–1233 (1995).

9. 9.

French, G. L., Shannon, K. P. & Simmons, N. Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase. J. Clin. Microbiol. 34, 358–363 (1996).

10. 10.

Weinreich, D. M. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312, 111–114 (2006).

11. 11.

Mroczkowska, J. E. & Barlow, M. Fitness trade-offs in blaTEM evolution. Antimicrob. Agents Chemother. 52, 2340–2345 (2008).

12. 12.

Tan, L., Serene, S., Chao, H. X. & Gore, J. Hidden randomness between fitness landscapes limits reverse evolution. Phys. Rev. Lett. 106, 198102 (2011).

13. 13.

Jacquier, H. et al. Capturing the mutational landscape of the beta-lactamase TEM-1. Proc. Natl Acad. Sci. USA 110, 13067–13072 (2013).

14. 14.

Zhang, Z., Yu, Y., Musser, J. M. & Palzkill, T. Amino acid sequence determinants of extended spectrum cephalosporin hydrolysis by the class C P99 beta-lactamase. J. Biol. Chem. 276, 46568–46574 (2001).

15. 15.

Todd, P. A. & Benfield, P. Amoxicillin/clavulanic acid. Drugs 39, 264–307 (1990).

16. 16.

Gin, A. et al. Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination. Expert Rev. Anti-infective Ther. 5, 365–383 (2007).

17. 17.

Drawz, S. M. & Bonomo, R. A. Three decades of -lactamase inhibitors. Clin. Microbiol. Rev. 23, 160–201 (2010).

18. 18.

Jacoby, G. A. AmpC beta-lactamases. Clin. Microbiol. Rev. 22, 161–182 (2009).

19. 19.

Chen, Y., Minasov, G., Roth, T. A., Prati, F. & Shoichet, B. K. The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution. J. Am. Chem. Soc. 128, 2970–2976 (2006).

20. 20.

Nadjar, D. et al. Outbreak of Klebsiella pneumoniae producing transferable AmpC-type beta-lactamase (ACC-1) originating from Hafnia alvei. FEMS Microbiol. Lett. 187, 35–40 (2000).

21. 21.

Wachino, J.-I. et al. Horizontal transfer of blaCMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19. Antimicrob. Agents Chemother. 50, 534–541 (2006).

22. 22.

Lobkovsky, E. et al. Evolution of an enzyme activity: crystallographic structure at 2-A resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc. Natl Acad. Sci. USA 90, 11257–11261 (1993).

23. 23.

Dubus, A., Ledent, P., Lamotte-Brasseur, J. & Frère, J.-M. The roles of residues Tyr150, Glu272, and His314 in class C β-lactamases. Proteins Struct. Funct. Bioinf. 25, 473–485 (1996).

24. 24.

Lahiri, S. D. et al. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob. Agents Chemother. 58, 5704–5713 (2014).

25. 25.

Bush, K., Macalintal, C., Rasmussen, B. A., Lee, V. J. & Yang, Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob. Agents Chemother. 37, 851–858 (1993).

26. 26.

Monnaie, D. & Frere, J. M. Interaction of clavulanate with class C beta-lactamases. FEBS Lett. 334, 269–271 (1993).

27. 27.

Choi, H., Paton, R. S., Park, H. & Schofield, C. J. Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition. Org. Biomol. Chem. 14, 4116–4128 (2016).

28. 28.

Ehmann, D. E. et al. Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor. Proc. Natl Acad. Sci. USA 109, 11663–11668 (2012).

29. 29.

Papp-Wallace, K. M. & Bonomo, R. A. New β-Lactamase Inhibitors in the Clinic. Infect. Dis. Clin. North Am. 30, 441–464 (2016).

30. 30.

Wang, X. et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob. Agents Chemother. 58, 1774–1778 (2014).

31. 31.

Zhanel, G. G. et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73, 159–177 (2013).

32. 32.

Peri, A. M. et al. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn. Microbiol. Infect. Dis. https://doi.org/10.1016/j.diagmicrobio.2019.01.020 (2019).

33. 33.

Chaibi, E. B., Sirot, D., Paul, G. & Labia, R. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. 43, 447–458 (1999).

34. 34.

Helfand, M. S. et al. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. J. Biol. Chem. 278, 52724–52729 (2003).

35. 35.

Cabot, G. et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob. Agents Chemother. 58, 3091–3099 (2014).

36. 36.

Shields, R. K. et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob. Agents Chemother. 61, e02097–16 (2017).

37. 37.

Rosenkilde, C. E. H. et al. Collateral sensitivity constrains resistance evolution of the CTX-M-15 β-lactamase. Nat. Commun. 10, 618 (2019).

38. 38.

Thomas, V. L., McReynolds, A. C. & Shoichet, B. K. Structural bases for stability-function tradeoffs in antibiotic resistance. J. Mol. Biol. 396, 47–59 (2010).

39. 39.

Winkler, M. L. et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 59, 1020–1029 (2015).

40. 40.

Calvopiña, K. et al. Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates. Mol. Microbiol. 106, 492–504 (2017).

41. 41.

Livermore, D. M. et al. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae. J. Antimicrob. Chemother. 73, 3336–3345 (2018).

42. 42.

Barnes, M. D. et al. Deciphering the evolution of cephalosporin resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa. mBio 9, e02085–02018 (2018).

43. 43.

Wang, H. H. et al. Programming cells by multiplex genome engineering and accelerated evolution. Nature 460, 894–898 (2009).

44. 44.

Kelsic, E. D. et al. RNA structural determinants of optimal codons revealed by MAGE-Seq. Cell Syst. 3, 563–571.e6 (2016).

45. 45.

Nyerges, Á. et al. A highly precise and portable genome engineering method allows comparison of mutational effects across bacterial species. Proc. Natl Acad. Sci. USA 113, 2502–2507 (2016).

46. 46.

Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–461 (2010).

47. 47.

Krieger, F., Möglich, A. & Kiefhaber, T. Effect of proline and glycine residues on dynamics and barriers of loop formation in polypeptide chains. J. Am. Chem. Soc. 127, 3346–3352 (2005).

48. 48.

Caroff, N., Espaze, E., Bérard, I., Richet, H. & Reynaud, A. Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum β-lactamase production. FEMS Microbiol. Lett. 173, 459–465 (1999).

49. 49.

Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785–2791 (2009).

50. 50.

Sterling, T. & Irwin, J. J. ZINC 15–ligand discovery for everyone. J. Chem. Inf. Model. 55, 2324–2337 (2015).

51. 51.

Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).

## Acknowledgements

We thank Viktoria Lazar, Ákos Nyerges and Csaba Pal for bacterial strains and support with mutagenesis and Barak Shaer for graphic support. The work was supported in part by the US National Institutes of Health grant R01-GM081617 and by a grant from F. Hoffmann-La Roche Ltd (to R.K.).

## Author information

Authors

### Contributions

D.R., M.B., E.K., C.Z., A.H., and R.K. designed the project, D.R., E.S.T., and I.Y. conducted the experiments, D.R. and F.G. analyzed the data and D.R., I.Y., and R.K. wrote the manuscript with feedback from all authors.

### Corresponding author

Correspondence to Roy Kishony.

## Ethics declarations

### Competing interests

The authors declare no competing interests.

Peer review information Nature Communications thanks Rafael Peña-Miller, Alejandro Vila and the other, anonymous, reviewer for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Rights and permissions

Reprints and Permissions

Russ, D., Glaser, F., Shaer Tamar, E. et al. Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor. Nat Commun 11, 2029 (2020). https://doi.org/10.1038/s41467-020-15666-2

• Accepted:

• Published:

• ### Wet-dry cycles protect surface-colonizing bacteria from major antibiotic classes

• Yana Beizman-Magen
• Maor Grinberg

The ISME Journal (2021)

• ### Synergistic evaluation of Moringa oleifera extract and ß-lactam antibiotic to restore the susceptibility of methicillin-resistant Staphylococcus aureus

• Soma Vankwani
• Asma Ansari

Molecular Biology Reports (2021)

• ### Ubiquitous selection for mecA in community-associated MRSA across diverse chemical environments

• Olga Snitser
• Dor Russ
• Roy Kishony

Nature Communications (2020)